[Reuters] U.S. health insurers say Gilead hepatitis C drug too costly

May 21, 2014
By Bill Berkrot
May 21, 2014


The leading U.S. health insurance trade group on Tuesday hit out at the extremely high cost of new specialty medicines, accusing drugmakers of taking advantage of the insurance system by pricing products at unsustainable levels.

The latest salvo in the war on escalating U.S. healthcare costs came from AHIP – America’s Health Insurance Plans – and targeted Sovaldi, the new $84,000 hepatitis C treatment from Gilead Sciences Inc.

“Sovaldi has shown tremendous results, and it’s the kind of medical innovation we need to sustain. Unfortunately, the drug’s maker has priced it at an astronomical level that is not sustainable for consumers, innovation, or society,” AHIP said on its Coverage blog.


[button title=”Read More” link=”http://www.reuters.com/article/2014/05/20/us-insurance-gilead-sciences-drugcosts-idUSKBN0E029U20140520″ target=”_blank” size=”” color=”” class=””]